A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Epistemonikos ID: a71749199fdac687bf47c59d0c2dc0f6f94ba1f8
First added on: Mar 01, 2025